National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix G: Biographical Notes on Committee Members." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
414
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

Dr. Chin has served on many national committees related to infectious disease control, including the American Public Health Association Committee on Infectious Diseases, the National Advisory Committee on Immunization Practices, and the Armed Forces Epidemiology Board. He received a B.S. from the University of Michigan, an M.D. from the State University of New York, Downstate, and an M.P.H. from the University of California, School of Public Health, Berkeley.


PURNELL W.CHOPPIN recently became vice president and chief scientific officer of the Howard Hughes Medical Institute. Previously, he was Leon Hess Professor of Virology and vice president for academic programs at The Rockefeller University. He was at that university since 1957, where he began as a postdoctoral fellow. He became a professor in 1970. His research has been on the structure, replication, and mechanisms of pathogenesis of myxoviruses and paramyxoviruses; the structure and function of viral membranes; and viral-cell membrane interactions. He received an M.D. degree from Louisiana State University, and his residency training in internal medicine at Barnes Hospital, Washington University, St. Louis.


THEODORE C.EICKHOFF has been director of Internal Medicine at Presbyterian St. Luke’s Medical Center and professor of medicine at the University of Colorado School of Medicine, Denver, since 1981. From 1968 to 1981 he was head of the Division of Infectious Disease at the University of Colorado School of Medicine. He has participated in a number of vaccine development and evaluation studies, and is a member of the American College of Physicians’ Immunization Advisory Committee. Presently, he is chairman of the Vaccines and Related Biological Products Advisory Committee, National Center for Drugs and Biologics, Food and Drug Administration, and is president of the Infectious Diseases Society of America. He received his M.D. degree from Case Western Reserve University School of Medicine and conducted his internal medicine residency and infectious disease fellowship training at the Harvard Medical Unit, Boston City Hospital.


FRANCIS A.ENNIS has been a professor of medicine and of molecular genetics and microbiology at the University of Massachusetts Medical School since 1982. From 1973 to 1981, he was director of the Division of Virology at the Bureau of Biologics in the Food and Drug Administration, and from 1970 to 1973 he was co-director of the Division of Infectious Diseases at Boston University Medical School. His research interests concern immune responses to virus infections and vaccines. He has an A.B. degree from Boston College and an M.D. degree from Tufts University.


HARVEY V.FINEBERG became dean at the Harvard School of Public Health in 1984 and had been a faculty member there since 1973. His research interests include the innovation and diffusion of new medical technology, the evaluation of medical practices, the application of decision sciences to health care, and the interface between medical science and public policy. He holds A.B., M.D., and Ph.D. degrees from Harvard.

Page
414
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)